Effectiveness of bedaquiline-containing regimens in multidrug-resistant tuberculosis: systematic review and meta-analysis
Keywords:
antitubercular agents; meta-analysis; treatment expectations; tuberculosis, multidrug-resistant; systematic reviewAbstract
Introduction: Tuberculosis control is significantly hindered by the emergence of strains resistant to isoniazid and rifampicin, a condition defined as multidrug-resistant tuberculosis. In response to this challenge, bedaquiline is integrated into all-oral regimens with superior tolerance and patient adherence.
Objective: To determine the effectiveness of bedaquiline-containing therapeutic regimens in adult patients with multidrug-resistant tuberculosis.
Methods: A systematic review was conducted of articles published on PubMed, ScienceDirect, SciElo, LILACS, Europe PMC, Biomed Central and Global Index Medicus between 2020-2025. Clinical studies, comparative studies, multicenter studies, observational studies, and randomized controlled trials involving adults diagnosed with multidrug-resistant and rifampicin-resistant tuberculosis treated with bedaquiline. Primary outcomes were treatment success and mortality; secondary were QT interval prolongation, hepatotoxicity, neuropathy, nephrotoxicity and ototoxicity. Risk ratios were pooled through a meta-analysis, and subgroup analyses were performed to identify sources of heterogeneity.
Results: Data from 10 studies involving 6,521 patients were pooled and 2,393 were treated with bedaquiline. Bedaquiline-containing regimens significantly improved treatment success (RR = 1.25; 95% CI: 1.17–1.35; p < 0.001). Mortality was reduced (RR = 0.71; 95% CI: 0.58-0.88; p = 0.002), although this effect was driven by the largest study. Subgroup analyses confirmed the superiority of bedaquiline over injectable agents, showing higher success rates (RR = 1.29; 95% CI: 1.21–1.37; p < 0.001).
Conclusions: Bedaquiline-containing regimens suggest significant improvement on treatment outcomes compared to conventional regimens. However, further evidence is required to confirm the impact on mortality.
Downloads
References
1. Switzerland. World Health Organization. Global tuberculosis report 2025 [Internet]. Switzerland, Geneva; 2025. [acceso: 17/04/2026]. Disponible en: https://iris.who.int/server/api/core/bitstreams/e97dd6f4-b567-4396-8680-717bac6869a9/content
2. Falzon D, Schünemann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update [Internet]. Eur Respir J. 2017; 49(3):1602308. DOI: 10.1183/13993003.02308-2016
3. Ngoc NB, Vu Dinh H, Thuy NT, Quang DV, Huyen CTT, Hoa NM, et al. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam [Internet]. PLOS ONE. 2021;16(9):e0255357. DOI: 10.1371/journal.pone.0255357
4. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis [Internet]. Cold Spring Harb Perspect Med. 2015;5(9):a017863. DOI: 10.1101/cshperspect.a017863
5. World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) [Internet]. Geneva: WHO; 2018. [acceso: 17/04/2026]. Disponible en: https://www.who.int/publications/i/item/WHO-CDS-TB-2018.18
6. Al Omar MFS, Alchikhsuliman IEM, Awad SM, Rajab N, Alawi YM, Ibrahim LYM, et al. Hepatic Safety of Bedaquiline, Delamanid, and Pretomanid: A Systematic Review and Meta-analysis [Internet]. Int J Mycobacteriology. 2025;14(4):309. DOI: 10.4103/ijmy.ijmy_97_25
7. Page M, McKenzie J, Bossuyt P, Boutron I, Hoffann T, Mulrow C, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas [Internet]. Rev Esp Cardiol. 2021;74(9):790-9. DOI: https://doi.org/10.1016/j.recesp.2021.06.016
8. Nápoles-Zaldivar Y, Nodarse-Palacios IM. Systematic review and meta-analysis of effectiveness of bedaquiline-containing regimens in multidrug-resistant tuberculosis [Internet]. PROSPERO. 2026. [acceso:24/04/2026]. Disponible en: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261354749
9. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials [Internet]. BMJ. 2019;l4898. DOI: 10.1136/bmj.l4898
10. ROBINS-I V2 tool [Internet]. Risk of bias tool; 2022. [acceso: 04/04/2026]. Disponible en: https://www.riskofbias.info/welcome/robins-i-v2
11. McGuinness LA, Higgins JPT. Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessments [Internet]. Res Synth Methods. 2021;12(1):55-61. DOI: 10.1002/jrsm.1411
12. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2023. [acceso: 29/05/2026]. Disponible en: https://www.gradepro.org
13. Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens [Internet]. Clin Infect Dis Off Publ Infect Dis Soc Am. United States; 2020;71(9):2336-44. DOI: 10.1093/cid/ciz1107
14. Pai H, Ndjeka N, Mbuagbaw L, Kaniga K, Birmingham E, Mao G, et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis [Internet]. BMC Infect Dis. 2022;22(1):870. DOI: 10.1186/s12879-022-07861-x
15. Zhang S-J, Yang Y, Sun W-W, Zhang Z-S, Xiao H-P, Li Y-P, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China [Internet]. BMC Infect Dis. 2022;22(1):715. DOI: 10.1186/s12879-022-07693-9
16. Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, et al. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study) [Internet]. Am J Respir Crit Care Med. England; 2022;205(10):1214-27. DOI: 10.1164/rccm.202107-1779OC
17. Fu L, Zhang X, Xiong J, Sun F, Weng T, Li Y, et al. Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: A multicenter prospective cohort study [Internet]. Int J Infect Dis. 2023;135:101-8. DOI: 10.1016/j.ijid.2023.08.001
18. Kim JH, Lee H, Oh I-S, Jeong HE, Bea S, Jang SH, et al. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study [Internet]. J Microbiol Immunol Infect. 2023;56(4):842-52. DOI: 10.1016/j.jmii.2023.04.009
19. Afifi M, Amin W, Helal D, Ashmawy R, El-Maradny YA, Khalifa N, et al. Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt [Internet]. Sci Rep. 2024;14(1):16247. DOI: 10.1038/s41598-024-65063-8
20. Santos AP, Benace CJJ, de Medeiros Leung JA, Kritski AL, de Queiroz Mello FC. Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil - a real-world evidence study using a retrospective design [Internet]. BMC Infect Dis. England; 2024;24(1):1112. DOI: 10.1186/s12879-024-09993-8
21. Jing W, Wang Q, Wang J, Ma L, Huang M, Wang J, et al. New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China [Internet]. Open Forum Infect Dis. 2025;12(2):ofaf020. DOI: 10.1093/ofid/ofaf020
22. Mvungi HC, Mbelele PM, Msaji KS, Mpagama SG, Semvua HH. Comparative Treatment Outcomes of Shorter Regimen in Modified All Oral Regimen with Injectable in Patients Treated for Rifampicin-resistant/Multidrug-resistant Tuberculosis in Tanzania [Internet]. Int J Mycobacteriology. 2025;14(4):340-6. DOI: 10.4103/ijmy.ijmy_98_25
23. Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, et al. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [Internet]. Am J Respir Crit Care Med. 2025;211(1):15-33. DOI: 10.1164/rccm.202410-2096ST
24. Fekadu G, Tolossa T, Bekele F, Chen X, He Y, Yu J, et al. Impact of all-oral bedaquiline-based shorter regimens in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis [Internet]. BMJ Glob Health. 2025;10(4):e018220. DOI: 10.1136/bmjgh-2024-018220
25. Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakidis P, et al. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis [Internet]. Lancet. 2020;396(10248):402-11. DOI: 10.1016/S0140-6736(20)31316-7
26. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis [Internet]. Lancet Respir Med. 2020;8(4):383-94. DOI: 10.1016/S2213-2600(20)30047-3
27. Nyang’wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis [Internet]. N Engl J Med. 2022;387(25):2331-43. DOI: 10.1056/NEJMoa2117166
28. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline [Internet]. Am J Respir Crit Care Med. 2019;200(10):e93-142. DOI: 10.1164/rccm.201909-1874ST
29. Hasan T, Medcalf E, Nyang’wa B-T, Egizi E, Berry C, Dodd M, et al. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis [Internet]. Clin Infect Dis. 2023;78(3):730-41. DOI: 10.1093/cid/ciad653
30. Bernal O, Lopez R, Montoro E, Avedillo P, Westby K, Ghidinelli M. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas [Internet]. Int J Tuberc Lung Dis. 2020;24(10):1058-62. DOI: 10.5588/ijtld.20.0111
31. Global Drug Facility. Medicines Catalog [Internet]. Geneva: Global Drug Facility; 2026. [acceso: 28/05/2026]. Disponible en: https://www.stoptb.org/sites/default/files/documents/GDF_Medicines_Catalog.pdf
32. Ministerio de Salud Pública. Resolución Ministerial 277/2014. Programa Nacional de Control de la Tuberculosis. Manual de Normas y Procedimientos [Internet]. La Habana: Editorial Ciencias Médicas; 2014 [acceso: 28/05/2026]. Disponible en http://www.sld.cu/galerias/pdf/sitios/tuberculosis/programa_2015.pdf
33. Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2024 [Internet]. La Habana: Editorial Ciencias Médicas; 2025 [acceso: 28/05/2026]. Informe Nro.: 53. Disponible en: https://temas.sld.cu/estadisticassalud/publicaciones-2/anuario-estadistico-de-salud/
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Yoander Nápoles-Zaldivar, Ivonne María Nodarse-Palacios, Edilio Silva-Velasco, Juan Carlos Báster-Moro, Luis Aníbal Alonso-Betancourt

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.

